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The authors have advised that [Table 1](#T0001){ref-type="table"} on pages 58 and 59 is incorrect. The correct table is shown below. Table 1Baseline Characteristics of Different GroupsVariableKOA\
(n=59)\
Group IKOA Patients with FM (n=32\
Group IIFM\
(n=30)\
Group IIIP valueDemographicAge (years), mean ± SD53.4 ± 7.247.3 ± 4.637.5 ± 6.9\<0.001\*\
P1\<0.001\*, p2\<0.001\*, p3\<0.001\*BMI, mean ± SD33.4 ± 3.133.3 ± 3.429.5 ± 3.9\<0.001\*\
p1\<0.001\*, p2\<0.001\*, p3=0.8Residence (rural: urban)34:2522:1018:120.58Marital status (married: not married)49:1023:9)19:110.11Educational level (literate: illiterate)39:2026:626:40.07ClinicalDisease duration (years), median (IQR)3 (2-5)2 (1-3.5)2 (2-3)0.07KL grades, n (%) I16 (27.1)18 (56.3)\-\-\--0.02\* II17 (28.8)7 (21.9)\-\-\-- III26 (44.1)7 (21.9)\-\-\--VAS, median (IQR)3 (2.0-4.75)6 (5-8)5 (3-7)\<0.001\*\
p1=0.002\*, p2=0.04\*, p3\<0.001\*PSQI, mean ± SD7.5 ± 1.712.5 ± 2.59.1 ± 2.7\<0.001\*\
P1\<0.001\*, p2\<0.001\*, P3\<0.001\*PASS20, mean ± SD35.9 ± 8.447.8 ± 10.940.5 ± 8.6\<0.001\*\
p1=0.02\*, p2=0.005\*, p3\<0.001\*BDI-II, median (IQR)5 (2-7)14 (9-17.5)22.5 (18-27)\<0.001\*\
p1\<0.001\*, p2\<0.001\*, p3\<0.001\*Lequesene score, median (IQR)5 (4-7)7 (5.5-12)\-\-\--\<0.001\*FIQ, mean ± SD\-\-\--49.5 ± 20.742.8 ± 13.20.14Quality of lifePhysical, mean ± SD49.8 ± 14.747.6 ± 14.162.1 ± 14.4\<0.001\*\
p1=\<0.001\*, p2=\<0.001\*, p3=0.5Cognitive, mean ± SD55.6 ± 1549.9 ± 16.651.3 ± 14.80.2Affective, mean ± SD53.5 ± 14.334.4 ± 17.347.6 ± 15.1\<0.001\*\
p1=0.07, p2=0.002\*, p3\<0.001\*Social, mean ± SD50.5 ± 15.245.8 ± 13.855.2 ± 12.40.04\*\
P1=15, p2=0.006\*, p3=0.14Economic, mean ± SD55.2 ± 19.154.8 ± 22.560.9 ± 16.50.36Ego, mean ± SD47.8 ± 1634.9 ± 15.935.9 ± 14.9\<0.001\*\
p1=0.001\*, p2=0.8, p3\<0.001\*MedicationsAcetaminophen, n (%)49 (83)20 (62.5)15 (50)0.004\*NSAIDS, n (%)46 (78)27 (84.4)22 (73.3)0.6Antidepressant, n (%)4 (6.8)12 (37.5)27 (90)\<0.001\*Gabapentinoids, n (%)9 (15.3)16 (50)24 (80)\<0.001\*Chondroprotctives, n (%)46 (78)21 (65.6)0 (0)0.3[^1][^2]

The authors apologize for this error.

[^1]: **Notes:** P1: between KOA group and FM group; p2: between FM group and KOA patients with FM co-morbidity group; p3: between KOA group and KOA patients with FM co-morbidity group. \*p\<0.05.

[^2]: **Abbreviations:** KOA, knee osteoarthritis; FM, fibromyalgia; BMI, body mass index; KL, Kellgren and Lawrence; VAS, visual analog scale; PSQI, Pittsburgh Sleep Quality Index; PASS20, Pain Anxiety Symptom Scale Short Form 20; BDI-II, Beck Depression Inventory; FIQ, Fibromyalgia Impact Questionnaire; NSAIDS, non-steroidal anti-inflammatory drugs.
